Education
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (VRCA)
:VRCA
VRCA Stock Chart & Stats
$8.05
-$0.03(-3.87%)
At close: 4:00 PM EST
$8.05
-$0.03(-3.87%)
Day’s Range― - ―
52-Week Range$3.28 - $9.82
Previous CloseN/A
Volume115.12K
Average Volume (3M)311.93K
Market Cap
$76.39M
Enterprise Value$55.54M
Total Cash (Recent Filing)$21.10M
Total Debt (Recent Filing)$35.74M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Feb 26, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding9,490,035
10 Day Avg. Volume219,168
30 Day Avg. Volume311,931
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-3.68
Price to Sales (P/S)4.79
P/FCF Ratio-0.59
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit1.96
Enterprise Value/Ebitda-3.39
Forecast
1Y Price Target
$18.00Price Target Upside123.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$37.13M
Bulls Say, Bears Say
Bulls Say
Operational FundingNon-dilutive financing was secured, providing operational funding through 2025 and into 2026.
Program AdvancementThe company plans to advance its VP-315/basal cell carcinoma program to a key study phase, pending financial support.
Sales GrowthYcanth sales increased by 33%, slightly surpassing market expectations.
Bears Say
Financial StabilityA 'going concern' remains despite the recent financing achievements.
Profitability ConcernsThe company is currently not profitable, making a long-term financial solution necessary.
Verrica Pharmaceuticals News
VRCA FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $3.28 and its highest was $9.82 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is $76.39M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Feb 26, 2026 which is in 68 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Nov 14, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.378 by $0.348.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.81.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 9,490,035 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.378. Following the earnings report the stock price went down -5.089%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in VRCA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verrica Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (123.60% Upside)
$18.00 (123.60% Upside)
Blogger Sentiment
Bullish
VRCA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 325.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $18.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.3%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
24.20%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals (VRCA) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for skin diseases. The company is primarily engaged in the dermatology sector, with a core focus on advancing therapies for conditions such as common warts and other skin-related ailments. Verrica's lead product candidate, VP-102, is a proprietary drug-device combination that utilizes a novel formulation of cantharidin for the treatment of warts, positioning the company as a key player in the dermatological therapeutics market.
VRCA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in YCANTH dispensations, strategic partnerships, and positive regulatory feedback, offset by challenges like seasonality impacts and a lengthy EU filing process.View all VRCA earnings summariesVRCA Stock 12 Month Forecast
Average Price Target
$18.00
▲(123.60% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---